SCHEMBL3751853

SCHEMBL3751853

CC1(C)CC(=O)c2sc(N3CCOCC3)c(-c3ccc(C(=O)O)cc3)c2C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 6/20 0.42
PIK3CG P48736 3/20 0.42
PIK3CD O00329 2/20 0.42
PIK3CB P42338 2/20 0.42
BRD4 O60885 2/20 0.38
HSD17B10 Q99714 1/20 0.38
MAPT P10636 4/20 0.37
ALDH1A1 P00352 3/20 0.37
APAF1 O14727 2/20 0.37
POLB P06746 2/20 0.37
MTOR P42345 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
KDM4E B2RXH2 2/20 0.36
RARB P10826 1/20 0.35
RARA P10276 1/20 0.35
RARG P13631 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
KMO O15229 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3763668 0.89 PIK3CA (0.42) PIK3CAPIK3CGPIK3CDPIK3CBBRD4
SCHEMBL3766002 0.88 PIK3CA (0.45) PIK3CAPIK3CGPIK3CDPIK3CBBRD4
SCHEMBL3754752 0.88 PRKDC (0.45) PIK3CAPIK3CGPIK3CDPIK3CBBRD4
SCHEMBL3755564 0.86 PIK3CA (0.45) PIK3CAPIK3CGPIK3CDPIK3CBBRD4
SCHEMBL3757774 0.85 PIK3CA (0.41) PIK3CAPIK3CGPIK3CDPIK3CBBRD4
SCHEMBL3766696 0.85 POLB (0.43) PIK3CAPIK3CGPIK3CDPIK3CBMAPT
SCHEMBL3760606 0.84 PRKDC (0.46) PIK3CAPIK3CGPIK3CDPIK3CBBRD4
SCHEMBL3769513 0.84 GABRG2 (0.50) PIK3CAPIK3CGPIK3CDPIK3CBBRD4
SCHEMBL3755814 0.82 NPC1 (0.41) PIK3CAPIK3CGPIK3CDPIK3CBBRD4
SCHEMBL3760149 0.82 PIK3CA (0.37) PIK3CAPIK3CGPIK3CDPIK3CBBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA PIK3CA 3/4885PIK3CG 12/4885PIK3CD 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.